The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive decline compared to placebo over 78 weeks, cautioning against off-label use.